Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus investigator-choice chemotherapy in previously treated metastatic urothelial cancer
NL-OMON44766Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, paclitaxel, docetaxel and vinflunine in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2015; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON44766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44766.